SyntheMed Assembles Sales Force For Repel-CV Cardiac Adhesion Barrier
This article was originally published in The Gray Sheet
Executive Summary
SyntheMed will launch its newly approved Repel-CV cardiac surgery adhesion barrier in the United States through two or three direct sales reps and a "much more significant" force of independent distributors, according to CEO Robert P. Hickey